SurVaxM Vaccine for High-Risk Lung Cancer Prevention

This study aims to explore how a specific vaccine called SurVaxM can potentially help prevent lung cancer in people who are at a high risk of developing the disease. SurVaxM is designed to stimulate the body's immune system to target survivin, a protein often found in cancer cells. By encouraging an immune response against this protein, the study hopes to reduce the chances of cancer developing. Understanding how well this vaccine works could lead to new prevention strategies for people who face a high risk of lung cancer, offering a proactive approach to cancer care. Participants in the study receive the SurVaxM vaccine through a series of injections just under the skin, along with another substance called montanide, and a medication named sargramostim to boost the immune response. These injections are given on a schedule over several weeks, with an additional booster shot later on. The study monitors the participants' immune responses by regularly collecting blood samples and checking whether the vaccine is prompting the desired immune reactions. Safety and any side effects are closely watched to ensure the well-being of participants. Following the treatment phase, participants continue to be monitored to assess the long-term effects and benefits of the vaccine.